Key takeaways
- South African product information lists vortioxetine as Brintellix for major depressive disorder and reducing relapse risk in adults. SAHPRA-approved Brintellix information.
- An eight-week trial found improvements on cognitive tests in adults with depression. It was not a study of healthy people seeking better focus. Randomised cognition trial.
- A switching trial found greater improvement in sexual function with vortioxetine than escitalopram in a specific group already experiencing SSRI-related problems. Randomised switching trial.
- Sexual side effects remain possible, and nausea is common. A different serotonin profile does not mean a side-effect-free antidepressant. South African prescribing information.
Feeling less depressed but still struggling to follow a conversation is frustrating. So is finding that a treatment helping your mood has changed your sex life. Both concerns deserve more than “give it time”.
Those are two reasons people ask about vortioxetine, including the Trintellix name in the catalogue. In South Africa, the approved information cited here uses Brintellix. The useful question is what the evidence says about the symptom you want to improve, not whether a newer-sounding name promises a better result.
Can vortioxetine help the cognitive symptoms of depression?
There is trial evidence for improvement, but it should not be presented as a general brain boost.
In a randomised trial involving 602 adults with recurrent, moderate-to-severe major depression, vortioxetine improved a combined measure of processing speed and memory compared with placebo over eight weeks. The researchers also analysed whether this simply reflected mood improvement. Their analysis suggested part of the cognitive effect was independent, but it does not prove exactly how the medicine produced that effect. Cognition trial.
The study was sponsored by the medicine’s developers, Lundbeck and Takeda. That does not erase its findings, but makes study design, duration and replication worth considering. Cognitive test gains also do not guarantee that every person’s concentration at work will recover.
Persistent difficulty thinking can have several contributors. The thyroid treatment article explores one different setting in which symptoms can persist despite treatment; it is not a reason to assume a thyroid problem or add another medicine.
Are sexual side effects less likely than with an SSRI?
A useful switching study supports that possibility for some patients, not a universal advantage.
The trial enrolled 447 adults whose depression was well treated but who had sexual dysfunction while taking an SSRI. They switched to vortioxetine or escitalopram. Over eight weeks, sexual-function scores improved more in the vortioxetine group, while antidepressant benefit was maintained in both groups. Switching trial.
That answers a narrower question than “which antidepressant causes the fewest sexual side effects?”. These participants already had a problem on treatment. The results do not establish the same advantage for everyone starting their first antidepressant, and vortioxetine itself can cause sexual dysfunction.
| Your main concern | What the evidence can help you ask |
|---|---|
| Concentration remains poor | Were similar symptoms measured, and in people with my diagnosis? |
| Sexual function changed on treatment | Is a supervised switch reasonable, and how will mood be monitored? |
| Nausea or other effects are disruptive | Is the overall benefit still worthwhile? |
What makes vortioxetine different, and what does not change?
It affects serotonin signalling in several ways, but the number of receptor actions is not a ranking of antidepressant quality.
Vortioxetine inhibits serotonin reuptake and acts at several serotonin receptors. Describing it as “multimodal” is pharmacology, not proof that it will suit someone better than an SSRI. South African prescribing information.
The decision still needs to account for past response, adverse effects, other medicines and personal priorities. Wakefulness medicines address a different clinical question: our modafinil and armodafinil comparison explains why staying awake and treating depressive cognitive symptoms are not interchangeable goals.
What should be checked before a switch?
Other serotonin-affecting medicines, bipolar symptoms and early changes in mood all matter.
Nausea is a common drawback. Interactions with MAO inhibitors and other serotonergic medicines can be serious. Tell the prescriber about all medicines and supplements, and about previous periods of unusually elevated mood or reduced need for sleep. New or worsening suicidal thoughts require urgent help, particularly early in treatment or after changes. South African warnings.
Do and don’t
Do: Name the symptom you most want to improve and agree how mood, concentration and sexual function will be reviewed.
Don’t: Overlap or switch antidepressants without a prescribed plan, or assume “fewer side effects” means none.
